Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer

Protein synthesis is frequently dysregulated in cancer and selective inhibition of mRNA translation represents an attractive cancer therapy. Here, we show that therapeutically targeting the RNA helicase eIF4A by Zotatifin, the first-in-class eIF4A inhibitor, exerts pleiotropic effects on both tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Na, Kabotyanski, Elena B., Saltzman, Alexander B., Malovannaya, Anna, Yuan, Xueying, Reineke, Lucas C., Lieu, Nadia, Gao, Yang, Pedroza, Diego A, Calderon, Sebastian J, Smith, Alex J, Hamor, Clark, Safari, Kazem, Savage, Sara, Zhang, Bing, Zhou, Jianling, Solis, Luisa M., Hilsenbeck, Susan G., Fan, Cheng, Perou, Charles M., Rosen, Jeffrey M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557675/
https://www.ncbi.nlm.nih.gov/pubmed/37808840
http://dx.doi.org/10.1101/2023.09.28.559973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557675/
https://www.ncbi.nlm.nih.gov/pubmed/37808840
http://dx.doi.org/10.1101/2023.09.28.559973

Ejemplares similares